^○Shigenobu TODA (Department of Psychiatry, Showa University School of Medicine)

^○Sebastien Bouret (CNRS/ ICM)

^○Seiichiro AMEMIYA^{1, 2, 3}, A David REDISH¹ (1. Department of Neuroscience, University of Minnesota, MN, USA, 2. RIKEN CBS, Saitama, Japan, 3. Department of Human Health Sciences, Tokyo Metropolitan University, Tokyo, Japan)

^○Yoshio IGUCHI (Department of Molecular Genetics, Fukushima Medical University, Fukushima, Japan)

^○Aya SHIRAMA^{1, 2}, Toshinobu TAKEDA³, Haruhisa OHTA², Shigenobu TODA^{4, 5} (1. Department of preventive intervention for psychiatric disorders, National institute of mental health, National center of Neurology and psychiatry, Tokyo, Japan, 2. Medical Institute of Developmental Disabilities Research, Showa University, 3. Faculty of Letters Ryukoku University, 4. Department of Psychiatry, Showa University East Hospital, Showa University, 5. Kanazawa University School of Medicine)

^○Takafumi MINAMIMOTO (Functional Brain Imaging, National Institute of Radiological Sci. QST)

^○橋本 謙二 (千葉大学社会精神保健教育研究センター)

^○Shigeru YOSHIDA (Development Plannning, Development Headquarters, Taisho Pharmacentical Co., LTD., Tokyo, Japan)

^○Haruhide KIMURA (Neuroscience Drug Discovery Unit, Research, Takeda Parmaceutical Company Limited)

^○Satoko BABA¹, Yoshiko TOMITA², Kazuki YABUUCHI³ (1. 薬理研究ユニット, 2. 臨床企画部, 3. CNS臨床開発)

^○Taishiro KISHIMOTO (Department of Neuropsychiatry, Keio University School of Medicine)

^○Sayaka TAKEMOTO-KIMURA (Neuroscience I, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan)

^○Masaaki OGAWA (Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan)

^○Ken-ichi AMEMORI (Hakubi Center for Advanced Research, Primate Research Institute, Kyoto University)

^○Saori C. TANAKA¹, Yuki SAKAI^{1, 3}, Yu TAKAGI^{1, 2} (1. ATR Brain Information Communication Research Lab. Group, Japan, 2. University of Oxford, Oxford Centre for Human Brain Activity, United Kingdom, 3. Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

^○Tetsurou KIKUCHI (New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd.)

^○Tetsuro OHMORI (Department of Psychiatry, Tokushima University)

^○Tetsuro KIKUCHI (New Drug Research Division, Pharmaceutical Business Division, Otsuka Pharmaceutical Co., Ltd.)

^○Kazuki YABUUCHI¹, Kenneth KOBLAN², Robert GOLDMAN², Justine KENT², Seth HOPKINS², Antony LOEBEL² (1. Drug Development Division, Sumitomo Dainippon Pharma Co., Ltd., Tokyo, Japan, 2. Sunovion Pharmaceuticals Inc.)

^○Hidehiro OSHIBUCHI (Department of Psychiatry, Tokyo Women's Medical University)

^○Jun ISHIGOOKA (Institute of CNS Pharmacology)

^○Tomiki SUMIYOSHI (Department of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health National Center of Neurology and Psychiatry)

^○Manabu MAKINDOAN (Department of Psychiatry, Nara Medical University, Japan)

^○Madoka MATSUMOTO (Department of Preventive Intervention for Psychiatric Disorders, NIMH, NCNP)

^○Tomiki SUMIYOSHI (Department of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health National Center of Neurology and Psychiatry)

^○Tomiki SUMIYOSHI (Department of Preventive Intervention for Psychiatric Disorders National Institute of Mental Health National Center of Neurology and Psychiatry)

^○Shogo TOKUYAMA (Department of Clinical Pharmacy, School of Pharmaceutical sciences, Kobe Gakuin University)

^○Kazuya MIYAGAWA, Atsumi MOCHIDA-SAITO, Kazuhiro KUROKAWA, Minoru TSUJI, Hiroshi TAKEDA (Departmnent of Pharmacology, School of Pharmacy, International University of Health and Welfare, Tochigi, Japan)

^○Yamaguchi TAKU (Department of Pharmacotherapeutics and Neuropsychopharmacology, Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki Sasebo, Japan)

^○Ryota ARAKI, Takeshi YABE (Lab. of Funct. Biomol. Chem. Pharmacol., Faculty of Pharmaceutical Sciences, Setsunan Univ., Osaka, Japan)

^○Shogo TOKUYAMA (Department of Clinical Pharmacy, School of Pharmaceutical sciences, Kobe Gakuin University)

^○Hiroshi TAKEDA (Department of Pharmacology, School of Pharmacy, International University of Health and Welfare)

^○Masahiko FUNADA (Department of Drug Dependence Research, NIMH, NCNP)

^○Ken-ichi TOMIYAMA, Yoko AKUNE, Masahiko FUNADA (Department of Drug Dependence Research, NIMH, NCNP, Tokyo, Japan)

^○Shuso TAKEDA (Laboratory of Xenobiotic Metabolism and Environmental Toxicology, Faculty of Pharmaceutical Sciences, Hiroshima International University (HIU))

^○Kenichi MISHIMA, Keiichi IRIE (Deaprtment of Pharmacology, Faculty of Pharamaceutical Sciences, Fukuoka University, Fukuoka)

^○Masahiko FUNADA, Ken-ichi TOMIYAMA (Department of Drug Dependence Research, NIMH, NCNP, Tokyo, Japan)

^○Kenichi MISHIMA (Deaprtment of Pharmacology, Faculty of Pharamaceutical Sciences, Fukuoka University)

^○Masanori SAKAGUCHI¹, Iyo KOYANAGI¹, Alvaro CARRIER-RUIZ^{2, 3}, Pablo VERGARA¹, Sakthivel SRINIVASAN¹, Yuki SUGAYA^{2, 3}, Masatoshi KASUYA¹, Kaspar VOGT¹, Masafumi MURATANI⁴, Takaaki OHNISHI⁵, Singh SIMA¹, Yoan CHéRASSE¹, Toshie NAOI¹, Naoko KANEKO⁶, Kazunobu SAWAMOTO^{6, 7}, Takeshi SAKURAI¹, Thomas J MCHUGH⁸, Masanobu KANO^{2, 3}, Masashi YANAGISAWA¹, Kumar DEEPENDRA¹ (1. WPI-IIIS, 2. Department of Neurophysiology, Graduate School of Medicine, The University of Tokyo, 3. International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo Institutes for Advanced Study (UTIAS), 4. Department of Genome Biology, Faculty of Medicine, University of Tsukuba, 5. Graduate School of Information Science and Technology, The University of Tokyo, 6. Department of Developmental and Regenerative Biology, Nagoya City University Graduate School of Medical Sciences, 7. Division of Neural Development and Regeneration, National Institute for Physiological Sciences, 8. RIKEN Center for Brain Science, Wako, Saitama, Japan)

^○Hotaka FUKUSHIMA¹, Satoshi KIDA^{1, 2} (1. Department of Bioscience, Faculty of Life Sciences, Tokyo University of Agriculture, Tokyo, Japan, 2. Graduate School of Agriculture and Life Sciences, The University of Tokyo)

^○Manabu FUCHIKAMI¹, Shigeru MORINOBU² (1. Hiroshima University Hospital, Department of Psychiatry, 2. Department of Occupational Therapy, School of Health Science and Social Welfare, Kibi International University)

^○Toshinori CHIBA¹, Kentarou IDE^{1, 3}, Tetsufumi KANAZAWA², Ai KOIZUMI⁴, Mitsuo KAWATO¹, Kaoru AMANO⁵ (1. Advanced Telecommunications Research institute international, 2. Department of Neuropsychiatry,Osaka Medical College, 3. Flower of Light Clinic for Mind and Body, 4. Sony Computer Science Laboratories, Inc, 5. CiNet)

^○Kyosuke UNO^{1, 2}, Yoshiaki MIYAMOTO², Atsumi NITTA² (1. Lab of Mol. Pharmacol, Fac. of Pharm. Sci, Setsunan University, Hirakata, Japan, 2. Dep. of Pharmaceutical Thera. and Neuropharmacol., Fac. of Pharma. Sci., Grad. Sch. of Med. and Pharma. Sci., Univ. of Toyama, Toyama, Japan)

^○Akiko SHIMAMOTO¹, Havisha MUNJAL¹, Tonie FARRIS¹, Chris DAVIS¹, Alicia WILSON¹, Malcolm EDWARDS¹, Cindy MOORE³, Virginie RAPPENEAU¹, Charles K MESHUL^{2, 3} (1. Department of Neuroscience and Pharmacology, Meharry Medical College, 2. Department of Behavioral Neuroscience, Oregon Health and Science University, 3. VA Portland)

^○Izumi IIDA^{1, 2}, Masahiko WATANABE³, Kenji SAKIMURA², Miho TERUNUMA¹ (1. Division of Oral Biochemistry Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan, 2. Department of Animal Model Development, Brain Research Institute, Niigata University, 3. Department of Anatomy, Hokkaido University School of Medicine )

^○Tomoyuki FURUYASHIKI (Division of Pharmacology, Graduate School of Medicine, Kobe University, Kobe, Japan)

^○Masahiro NISHIBORI (Dept of Pharmacol, Okayama Univ Grd Sch Med, Dent & Pharmaceut Sci, Okayama, Japan)

^○Kinya OTSU (School of Cardiovascular Medicine and Sciences, King's College London, London, UK)

^○Masaaki IWATA (Division of Neuropsychiatry, Department of Brain and Neurosciences, Tottori University Faculty of Medicine)

^○Tomoyuki FURUYASHIKI (Division of Pharmacology, Graduate School of Medicine, Kobe University, Kobe, Japan)

^○Tadafumi KATO (Laboratory for Molecular Dynamics of Mental Disorders, RIKEN Center for Brain Science)

^○Jun HORIGUCHI (Department of Immune Neuropsychiatry,Shimane University School of Medicine)

^○Yuki MATSUDA¹, Taro KISHI^{1, 2} (1. Department of Psychiatry, Jikei University School of Medicin, Tokyo, Japan, 2. Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan)

^○Itaru MIURA (Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan)

^○Yoshiteru TAKEKITA (Department of Neuropsychiatry, Kansai Medical University)

^○Masayuki TAKASE (Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan)

^○Hirooki YABE (Department of Neuropsychiatry, Fukushima Medical University (FMU))

^○Fujio YOKOYAMA (Department of Psychiatry, Saitama Medical University, Saitama, Japan )

^○Takahiro MATSUOKA^{1, 2}, Takaki SHIMODE¹, Fujio YOKOYAMA¹, Kouji MATSUO¹ (1. Department of Psychiatry, Saitama Medical University Hospital, 2. Department of Psychiatric Emergency, Saitama Medical University International Medical Center. )

^○Akira IWANAMI (Department of Psychiary, Showa University, School of Medicine)

^○Kazuya ONO (Depertment.of Neuropsychiatry,ST.Marianna University School of Mdedicine Kanagawa Japan)

^○Kiyofumi YAMADA (Dept. Neuropsychopharmacology & Hospital Pharmcy, Nagoya University Graduate School of Medicine)

^○Soichiro IDE, Kazutaka IKEDA (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan)

^○Satoshi KIDA (Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, Japan)

^○Taku NAGAI (Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan)

^○Kazuki NAGAYASU, Naoya NISHITANI, Shuji KANEKO (Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan)

^○Satoshi KIDA (Graduate School of Agriculture and Life Sciences, The University of Tokyo)

^○Tetsuya SUHARA (National Institutes for Quantum and Radiological Science and Technology)

^○Hiroyuki MIZOGUCHI¹, Kiyofumi YAMADA² (1. Research Center for Next-Generation Drug Development, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan, 2. Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine)

^○Katsuhiko MIYAZAKI, Kayoko W MIYAZAKI, Kenji DOYA (Neural Computation Unit, Okinawa Institute of Science and Thechnology)

^○Toshiyuki HIRABAYASHI (National Institutes for Quantum and Radiological Science and Technology)

^○Takafumi MINAMIMOTO (National Institutes for Quantum and Radiological Science and Technology)

^○Takuya TAKAHASHI (Department of Physiology, School of Medicine, Yokohama City University, Yokohama, Japan)

^○Takuya TAKAHASHI (Department of Physiology, School of Medicine, Yokohama City University, Yokohama, Japan)

^○Harumasa TAKANO (Integrative Brain Imaging Center, National Center of Neurology and Psychiatry, Tokyo, Japan)

^○Keisuke TAKAHATA^{1, 2} (1. Department of Functional Brain Imaging Research National Institute of Radiological Sciences (NIRS) National Institutes for Quantum and Radiological Science and Technology (QST), 2. Department of Neuropsychiatry, Keio University School of Medicine)

^○Fumitoshi KODAKA (Department of Psychiatry, the Jikei University School of Medicine)

^○Takuya TAKAHASHI (Department of Physiology, School of Medicine, Yokohama City University, Yokohama, Japan)

^○Jun ISHIGOOKA (Institute of CNS Pharmacology)

^○Shigeyuki CHAKI¹, Kenji HASHIMOTO² (1. Research Headquarters, Taisho Pharmaceutical Co., Ltd., 2. Chiba University Center for Forensic Mental Health)

^○Yasunori MORIO, Tomiki SUMIYOSHI (National Center of Neurology and Psychiatry, Tokyo, Japan)

^○Hiroshi NAKAMURA¹, Koichiro WATANABE² (1. Medical Affairs, Sumitomo Dainippon Pharma Co.,Ltd. , 2. Department of Neuropsychiatry, Kyorin University School of Medicine)

^○Kazuyuki NAKAGOME (National Center of Neurology and Psychiatry)

^○Shinsuke KITO (Department of Psychiatry, Jikei University School of Medicine)

^○Masataka Wada (Neuropsychiatry department, Keio University, Tokyo, Japan)

^○Shinsuke KITO (Department of Psychiatry, Jikei University School of Medicine)

^○Noda YOSHIHIRO (Department of Neuropsychiatry, Keio University School of Medicine)

^○Takashi NAKAMAE (Department of Psychiatry, Graduate School of Medical Science, Kyoto Prefectural University of Medicine)

^○Yoshihiro NODA (Department of Neuropsychiatry, Keio University School of Medicine)

^○Fusao KATO (Department of Neuroscience, The Jikei University School of Medicine, Tokyo, Japan)

^○Fusao KATO (Department of Neuroscience, The Jikei University School of Medicine, Tokyo, Japan)

^○Satoshi UMEDA (Department of Psychology, Keio University, Tokyo, Japan)

^○Masayuki SEKIGUCHI (Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry)

^○Yutaka MATSUOKA (Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan)

^○Yutaka MATSUOKA (Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan)

^○Kunio YUI¹, Hitomi SASAKI¹, Yohei KAWASAKI², Ryoichi SHIROKI¹, George IMATAKA³ (1. Deprtment of Urology, Fujita Medical University, Aichi, Japan, 2. Chiba University Clinical Research Center, 3. Department of Pediatrics Dokkyo Medical University)

^○Atsuto ONODA^{1, 2}, Karin S. HOUGAARD^{5, 6}, Ulla VOGEL^{5, 6}, Ken TAKEDA³, Masakazu UMEZAWA⁴ (1. Department of Pediatrics, Nagoya University Graduate School of Medicine, 2. Research Fellow of Japan Society for the Promotion of Science,, 3. Department of Materials Science and Technology, Faculty of Industrial Science and Technology, Tokyo University of Science, 4. Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 5. National Research Centre for the Working Environment, NanoSafety Centre,, 6. Department of Public Health, University of Copenhagen)

^○Tsuyoshi HATTORI¹, Jureepon ROBOON¹, Mika TAKARADA-IEMATA¹, Hiroshi ISHII¹, Cherepanov M STANISLAV², Anna SHABALOVA², Hiroshi OKAMOTO⁴, Yasuhiko YAMAMOTO³, Haruhiro HIGASHIDA², Osamu HORI¹ (1. Department of Neuroanatomy, Kanazawa University Graduate School of Medical Sciences, 2. Research Center for Child Mental Development, Kanazawa University, 3. Department of Pharmaceutical and Health Science, Kanazawa University Graduate School of Medical Sciences, 4. Department of Biochemistry, Tohoku University Graduate School of Medicine)

^○Yuta KATAYAMA (Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan)

^○Kenji HASHIMOTO (Chiba University Center for Forensic Mental Health)

^○Hisamitsu TAKASE (Department of Pharmacy, Nippon Medical School Tamanagayama Hospital)

^○Hiroshi UENO (Pain & Palliative Care Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan)

^○Takayuki NAKAGAWA¹, Shinya SUZUKI², Mayako UCHIDA³, Hideki SUGAWARA⁴, Yukio SUGA⁵, Hideya KOKUBUN⁶, Yoshihiro UESAWA⁷, Hisamitsu TAKASE⁸ (1. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 2. Department of Pharmacy, National Cancer Center Hospital East, 3. Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, 4. Department of Pharmacy, Kagoshima University Hospital, 5. Department of Clinical Drug Informatics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University, 6. Tokyo University of Pharmacy and Life Sciences, 7. Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 8. Nippon Medical School Tama-Nagayama Hospital)

^○Mayako UCHIDA¹, Shinya SUZUKI², Yukio SUGA³, Hideki SUGAWARA⁴, Hideya KOKUBUN⁵, Yoshihiro UESAWA⁶, Takayuki NAKAGAWA⁷, Hisamitsu TAKASE⁸ (1. Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, 2. Department of Pharmacy, National Cancer Center Hospital East, 3. Department of Clinical Drug Informatics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University, 4. Department of Pharmacy, Kagoshima University Hospital, 5. Tokyo University of Pharmacy and Life Sciences, 6. Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 7. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 8. Nippon Medical School Tama-Nagayama Hospital)

^○Hideki SUGAWARA¹, Yukio SUGA², Mayako UCHIDA³, Shinya SUZUKI⁴, Yoshihiro UESAWA⁵, Takayuki NAKAGAWA⁶, Hisamitsu TAKASE⁷ (1. Department of Pharmacy, Kagoshima University Hospital, 2. Department of Clinical Drug Informatics, Faculty of Pharmacy, Institute of Medical, Pharmaceutical & Health Science, Kanazawa University, 3. Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, 4. Department of Pharmacy, National Cancer Center Hospital East, 5. Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 6. Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 7. Nippon Medical School Tama-Nagayama Hospital)

^○Takayuki NAKAGAWA (Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital)

^○Kazuo YAMADA (Department of Psychiatry, Tohoku Medical and Pharmaceutical University Hospital)

^○Makoto OHSAWA (Oido Clinic)

^○Yuuji OOMIYA, Kazushige MIZOGUCHI, Atsushi KANEKO (Tsumura Kampo Research Laboratories, Kampo Research & Development Division, Tsumura & Co.)

^○Tsuyoshi MIYAOKA (Matsue Aoba Hospital)

^○Katsunori IWASAKI (Department of Neuropharmacology, Fac. of Pharmaceutical Sci.,Fukuoka University, Fukuoka, Japan)

^○Katsunori IWASAKI (Department of Neuropharmacology, Fac. of Pharmaceutical Sci.,Fukuoka University)

^○Tomoyuki MURANO, Hideo HAGIHARA, Tsuyoshi MIYAKAWA (Division of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University)

^○Katsunori KOBAYASHI (Department of Pharmacology, Nippon Medical School, Tokyo, Japan)

Courtney Sullivan¹、Jarek Meller²、Ram Shukla³、Zoltan Sarnia⁴、Amy Ramsey⁵、Zhexing Wen⁶、Laura Rowland⁷、^○Robert McCullumsmith⁸ (1. Model Design Specialist at Taconic Biosciences, San Diego, CA, USA、2. Graduate Program Director for Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA、3. Assistant Professor, Department of Neurosciences, University of Toledo, Toledo, OH, USA、4. Professor, Neuroscientist at James Cook University, Queensland, Australia. 、5. Associate Professor, Department of Pharmacology and Toxicology, University of Toronto, Canada、6. Assistant Professor, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA、7. Associate Professor, Psychiatry, University of Maryland School of Medicine, Baltimore MD, USA、8. Professor and Chair, Department of Neurosciences, University of Toledo, Toledo, OH, USA)

^○Mitsuyuki MATSUMOTO (Virtual Venture Unit, Psychiatry, Astellas Research Institute of America, San Diego, USA)

^○Yoshiro OKUBO (Department of Neuropsychiatry, Nippon Medical School)

^○Ryosuke ARAKAWA^{1, 2} (1. Department of Clinical Neuroscience, Karolinska Institutet, 2. Department of Neuropsychiatry, Nippon Medical School)

^○Keisuke TAKAHATA^{1, 2} (1. Department of Functional Brain Imaging Research National Institute of Radiological Sciences (NIRS) National Institutes for Quantum and Radiological Science and Technology (QST), 2. Department of Neuropsychiatry, Keio University School of Medicine)

^○Amane TATENO, Takeshi SAKAYORI, Ryosuke ARAKAWA, Yoshiro OKUBO (Department of Neuropsychiatry, Nippon Medical School, Tokyo, Japan)

^○Tetsuya SUHARA (National Institutes for Quantum and Radiological Science and Technology)